Cisplatin and a potent platinum(IV) complex-mediated enhancement of TRAIL-induced cancer cells killing is associated with modulation of upstream events in the extrinsic apoptotic pathway

Carcinogenesis

Volumn 32, Issue 1, 2011, Pages 42-51

  Blanáthoma, Olga Vondálová ^a   Jelínková, Iva ^a   Szöor, Árpád ^a,b   Skender, Belma ^a   Souček, Karel ^a   Horváth, Viktor ^a   Vaculová, Alena ^a   Anděra, Ladislav ^a   Sova, Petr ^c   Szöllosi, János ^b   Hofmanová, Jiřina ^a   Vereb, György ^b   Kozubík, Alois ^a  

^a INSTITUTE OF MATHEMATICS   (Czech Republic)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c Lachema sro   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CISPLATIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; PLATINUM COMPLEX; AMANTADINE; BIS(ACETATO)(1 ADAMANTYLAMINE)AMMINEDICHLOROPLATINUM(IV); BIS(ACETATO)(1-ADAMANTYLAMINE)AMMINEDICHLOROPLATINUM(IV); DRUG DERIVATIVE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL KILLING; CELL MEMBRANE; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; ENDOCYTOSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INTERNALIZATION; LIPID RAFT; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; CELL SEPARATION; CONFOCAL MICROSCOPY; DRUG EFFECT; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; NEOPLASM; PHYSIOLOGY; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

AMANTADINE; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SEPARATION; CISPLATIN; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICROSCOPY, CONFOCAL; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PROTEIN TRANSPORT; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 79952117634     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq220     Document Type: Article

References (58)

1. Wajant,H. et al. (2005) Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev., 16, 55-76.
2. Walczak,H. et al. (1999) Tumoricidal activity of tumor necrosis factorrelated apoptosis-inducing ligand in vivo. Nat. Med., 5, 157-163.
3. Koschny,R. et al. (2007) The promise of TRAIL-potential and risks of a novel anticancer therapy. J. Mol. Med., 85, 923-935.
4. Hinz,S. et al. (2000) Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene, 19, 5477-5486.
5. Makhov,P. et al. (2008) Zinc chelation induces rapid depletion of the X-linked inhibitor of apoptosis and sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Cell Death Differ., 15, 1745-1751.
6. Ndozangue-Touriguine,O. et al. (2008) A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma. Oncogene, 27, 6012-6022.
7. MacFarlane,M. et al. (2005) TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res., 65, 11265-11270.
8. Kelley,R.F. et al. (2005) Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J. Biol. Chem., 280, 2205-2212.
9. Sheridan,J.P. et al. (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science, 277, 818-821.
10. Zhang,X.D. et al. (1999) Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res., 59, 2747-2753.
11. Scaffidi,C. et al. (1999) Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J. Biol. Chem., 274, 22532-22538.
12. Li,S. et al. (2002) Relief of extrinsic pathway inhibition by the Biddependent mitochondrial release of Smac in Fas-mediated hepatocyte apoptosis. J. Biol. Chem., 277, 26912-26920.
13. Vereb,G. et al. (2000) Cholesterol-dependent clustering of IL-2Ralpha and its colocalization with HLA and CD48 on T lymphoma cells suggest their functional association with lipid rafts. Proc. Natl Acad. Sci. USA, 97, 6013-6018.
14. Vereb,G. et al. (2003) Dynamic, yet structured: the cell membrane three decades after the Singer-Nicolson model. Proc. Natl Acad. Sci. USA, 100, 8053-8058.
15. Song,J.H. et al. (2007) Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res., 67, 6946-6955.
16. Eramo,A. et al. (2004) CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells. Eur. J. Immunol., 34, 1930-1940.
17. Lee,K.H. et al. (2006) The role of receptor internalization in CD95 signaling. EMBO J., 25, 1009-1023.
18. Kohlhaas,S.L. et al. (2007) Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. J. Biol. Chem., 282, 12831-12841.
19. Kondo,K. et al. (2006) Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosisinducing ligand against esophageal squamous cell carcinoma. Int. J. Cancer, 118, 230-242.
20. Evdokiou,A. et al. (2002) Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int. J. Cancer, 99, 491-504.
21. Psahoulia,F.H. et al. (2007) Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol. Cancer Ther., 6, 2591-2599.
22. Xu,L. et al. (2009) Oxaliplatin enhances TRAIL-induced apoptosis in gastric cancer cells by CBL-regulated death receptor redistribution in lipid rafts. FEBS Lett., 583, 943-948.
23. Abedini,M.R. et al. (2010) Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene, 29, 11-25.
24. Ganten,T.M. et al. (2004) Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ., 11, S86-S96.
25. Sudhakar,C. et al. (2008) Sp1-like sequences mediate human caspase-3 promoter activation by p73 and cisplatin. FEBS J., 275, 2200-2213.
26. Tsai,W.S. et al. (2006) Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin. Mol. Cancer Ther., 5, 2977-2990.
27. Turanek,J. et al. (2004) New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes. Anticancer Drugs, 15, 537-543.
28. Kozubik,A. et al. (2005) High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro. Biochem. Pharmacol., 69, 373-383.
29. Horvath,V. et al. (2006) Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells. Gynecol. Oncol., 102, 32-40.
30. Horvath,V. et al. (2007) Different cell cycle modulation following treatment of human ovarian carcinoma cells with a new platinum(IV) complex vs cisplatin. Invest. New Drugs, 25, 435-443.
31. Roubalova,E. et al. (2009) The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12. Invest. New Drugs, 28, 445-453.
32. Hrstka,R. et al. (2008) The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin. Anticancer Drugs, 19, 369-379.
33. Kvardova,V. et al. (2010) The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin. Mol. Cancer, 9, 147.
34. Sova,P. et al. (2005) Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 [(OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV)]. Int. J. Pharm., 288, 123-129.
35. Sova,P. et al. (2005) Preclinical anti-tumor activity of a new oral platinum( IV) drug LA-12. Anticancer Drugs, 16, 653-657.
36. Sova,P. et al. (2006) Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts. Anticancer Drugs, 17, 201-206.
37. Doubravska,L. et al. (2008) Wnt-expressing rat embryonic fibroblasts suppress Apo2L/TRAIL-induced apoptosis of human leukemia cells. Apoptosis, 13, 573-587.
38. Atienza,J.M. et al. (2006) Dynamic and label-free cell-based assays using the real-time cell electronic sensing system. Assay Drug Dev. Technol., 4, 597-607.
39. Livak,K.J. et al. (2001) Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-408.
40. Hofmanova,J. et al. (2009) Human fetal colon cells and colon cancer cells respond differently to butyrate and PUFAs. Mol. Nutr. Food Res., 53 (suppl. 1), S102-S113.
41. Falschlehner,C. et al. (2009) TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. Adv. Exp. Med. Biol., 647, 195-206.
42. Ganten,T.M. et al. (2006) Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin. Cancer Res., 12, 2640-2646.
43. Koschny,R. et al. (2007) TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology, 45, 649-658.
44. Lacour,S. et al. (2001) Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res., 61, 1645-1651.
45. Munshi,A. et al. (2002) Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Cancer Chemother. Pharmacol., 50, 46-52
46. Nagane,M. et al. (2000) Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res., 60, 847-853.
47. Kondo,K. et al. (2006) Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma. Surg. Today, 36, 966-974.
48. Kendrick,J.E. et al. (2008) Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model. Gynecol. Oncol., 108, 591-597.
49. Shin,J.N. (2005) Cisplatin inactivation of caspases inhibits death ligandinduced cell death in vitro and fulminant liver damage in mice. J. Biol. Chem., 280, 10509-10515.
50. Han,S.J. et al. (2009) TRAIL-induced cell death and caspase-8 activation are inhibited by cisplatin but not carboplatin. J. Gynecol. Oncol., 20, 113-116.
51. Hotta,T. et al. (2003) Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential. J. Orthop. Res., 21, 949-957.
52. Reddy,R.M. et al. (2004) Cisplatin enhances apoptosis induced by a tumorselective adenovirus expressing tumor necrosis factor-related apoptosisinducing ligand. J. Thorac. Cardiovasc. Surg., 128, 883-891.
53. Chen,J.J. (2008) Proteasome inhibitors enhance TRAIL-induced apoptosis through the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53 activation. J. Immunol., 180, 8030-8039.
54. Sun,M. et al. (2008) Sp1 is involved in 8-chloro-adenosine-upregulated death receptor 5 expression in human hepatoma cells. Oncol. Rep., 19, 177-185.
55. Lacour,S. et al. (2004) Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res., 64, 3593-3598.
56. Vanoosten,R.L. et al. (2005) Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol. Ther., 11, 542-552.
57. Akazawa,Y. et al. (2009) Death receptor 5 internalization is required for lysosomal permeabilization by TRAIL in malignant liver cell lines. Gastroenterology, 136, 2365-2376.
58. Werneburg,N.W. et al. (2007) Tumor necrosis factor-related apoptosisinducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins. J. Biol. Chem., 282, 28960-28970.